AC Immune SA enters into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals (Johnson & Johnson, NYSE: JNJ) to develop and commercialize therapeutic anti-Tau vaccines for the treatment of Alzheimer’s disease and potentially other tauopathies, including the lead therapeutic vaccine, ACI-35, that is currently in a phase Ib clinical trial in Alzheimer’s patients. Under the terms of the agreement, AC Immune will receive an upfront payment and is eligible to receive research, development and commercialization milestone payments potentially totaling up to USD 509 million (CHF 500 million as per Dec. 2014) and royalties on net sales.

Fenwick & West LLP and VISCHER AG represent AC Immune based in Lausanne, Switzerland. The Fenwick team is led by partner Jake Handy with Lisa Kenkel. The VISCHER team is lead by partner Matthias Staehelin with Christian Wyss.